Anavex Presents Compelling Data at World’s Largest Alzheimer’s Conference
VANCOUVER, BC – July 17, 2012
Anavex Life Sciences Corp. (“Anavex”) (OTCBB: AVXL) today announced new and dramatic data concerning its Alzheimer’s disease treatment candidate ANAVEX 2-73 and leading Alzheimer’s treatments Aricept® (donepezil HCl) and Namenda® (memantine HCl).A clear synergic effect of ANAVEX 2-73 with Aricept® (donepezil HCl) has been demonstrated in a scientific study conducted by Tangui Maurice, PhD, CNRS Research Director, Head of Team 2 “Endogenous Neuroprotection in Neurodegenerative Diseases”, at the University of Montpellier and INSERM, in France.
“This new study emphasizes the anti-amnesic and neuroprotective effects of ANAVEX 2-73, and for the first time describes the potential benefits of administering ANAVEX 2-73 with donepezil,” said Dr. Maurice. “ANAVEX 2-73 showed efficacy in reversing learning impairments and toxicity in pre-clinical models. The new data confirms both a restorative effect of ANAVEX 2-73, and in combination with donepezil the potential to boost the therapeutic efficacy of each drug.”
The new data was presented at the world’s largest gathering of dementia researchers at the Alzheimer’s Association International Conference® (AAIC) being held this week in Vancouver, British Columbia, Canada. The presentation is titled, “Neuroprotective efficacy of ANAVEX 2-73, a novel tetrahydrofuran derivative targeting the sigma-1 chaperone protein, in a mouse model of Alzheimer’s disease: Analyses of administration schedules and combination studies with donepezil and memantine.” Conducted jointly by INSERM at University of Montpellier and by Anavex Life Sciences Corp., details of the study are described on Anavex’s website https://anavex.com//files/2012-07-16_ANAVEX_2-73_Poster_AAIC.pdf.
About Anavex Life Sciences Corp.
Anavex Life Sciences Corp. (www.anavex.com) is a pharmaceutical company engaged in the development of novel drug candidates. Anavex utilizes its proprietary SIGMACEPTOR™ Platform to develop drug candidates targeting specific clinical indications. Lead compound ANAVEX 2-73, developed to treat Alzheimer’s through disease modification, is in human clinical trials. A Phase 1 single ascending dose study of ANAVEX 2-73 was successfully completed in Germany in 2011. Studies indicate that ANAVEX 2-73 demonstrates anti-amnesic and neuroprotective properties, and that it is well tolerated in doses up to 55mg. The company is preparing to embark on a multiple ascending dose clinical trial of ANAVEX 2-73 in 2012. Anavex is a publicly traded corporation quoted as AVXL.
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks and uncertainties inherent in drug discovery and development, which include, without limitation, the potential failure of development candidates to advance through preclinical studies or demonstrate safety and efficacy in clinical testing and the ability to pass clinical trials so as to move on to the next phase, our ability to finance development or satisfy the rigorous regulatory requirements for new drugs, our ability to attract and retain quality personnel, and that despite positive results, our competitors may offer better or cheaper alternatives. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.
For Further Information
Anavex Life Sciences Corp.
Research & Business Development